Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients†‡

Abstract

The individualized treatment strategy according to time to bDNA negativity failed to provide comparable efficacy compared with the standard of care. The inferiority of the individualized protocol may be explained by the use of a less sensitive HCV RNA assay, and also by underestimation of the importance of baseline viremia.